RevOpsis Therapeutics

After a very successful cell line development campaign using Asimov's CHO Edge system, we are excited to be partnering with Asimov for the development and commercialization of RO-104, our first-in-class trispecific biologic for the treatment of #nAMD and #DME! https://lnkd.in/ecrmbRKa Ramanath Bhandari, Ronil Patel, Ram Palanki, Jessi Prentice

Hot off the press!! 📢 RevOpsis Therapeutics is excited to share that we were awarded funds from the National Eye Institute (NEI) through an #SBIR grant to progress our first-in-class trispecific, RO-104, targeting VEGF-A, VEGF-C, and Ang2 for the treatment of #nAMD and #DME. Ramanath Bhandari, Ram Palanki, Ronil Patel, Jessi Prentice, Li Xu https://lnkd.in/gvr_gDgJ

RevOpsis is excited to be presenting at the H.C. Wainwright & Co., LLC Annual Ophthalmology Virtual Conference on August 15, 2024. Our CBO, Ronil Patel, and CEO, Ramanath Bhandari, will be available during the conference for 1 on 1 meetings. Join us!

Another productive and exciting week for RevOpsis Therapeutics in Stockholm at the annual ASRS – American Society of Retina Specialists meeting. A special thanks to Subhransu Ray for presenting the Preclinical Analysis of a Novel #Trispecific Antibody, RO-104, for Use in Retinal Neovascular Disease. We appreciate everyone who facilitated this abstract and are looking forward to our next data release. Stay tuned! Ramanath Bhandari, Ram Palanki, Ronil Patel, Ramesh R. Bhatt, Li Xu, Jessi Prentice, Arshad M. Khanani, Jeff Heier, Mark Barakat, MD, Peter Kaiser

Ramanath Bhandari, MD, FASRS, of RevOpsis Therapeutics discusses the development of RO-104 for the treatment of retinal disease. 🔗 below #OcularSurgeryNews #Retina #CTS_Retina CTS Retina https://lnkd.in/ecHWeJTp

🚀 Thrilled to announce the appointment of our new #CBO, Ronil Patel! We are happy to have him on board, and are very excited to be building such a strong, capable, and committed team! ⭐ Learn more about Ronil and what he brings to RevOpsis in our attached press release. #dreamteam #biotech https://lnkd.in/d2HiGxEa

🌟 Exciting News! 🌟 RevOpsis Therapeutics is thrilled to announce our strategic collaboration with Kemwell Biopharma! This partnership will accelerate the development and commercialization of our lead candidate, RO-104, a first-in-class trispecific biologic for treating neovascular age-related macular degeneration (nAMD). Together with Kemwell's manufacturing excellence and our innovative Rev-Mod platform, we are poised to bring transformational medicines to patients worldwide. #Biotechnology #Pharmaceuticals #Innovation #Healthcare #Partnership

Another amazing CTS Retina meeting in the books. Our interim CEO, Ramanath Bhandari, was able to speak on behalf of #RevOpsis and our lead asset, RO-104, a first-in-class #trispecific for #nAMD, targeting VEGF A, VEGF C, and Ang2. Thank you Arshad M. Khanani, Jeff Heier, and Peter Kaiser for the opportunity to present to such a robust audience!

RevOpsis recently had the opportunity to participate in the immersive Great Lakes I-Corps Hub program through the U.S. National Science Foundation (NSF). The importance of an #entrepreneurial training program which focuses on moving beyond the science and into the commercialization process cannot be overemphasized. As a company founded by medical professionals and scientists, having a program that not only provides these basic learnings and tools, but also helps build such a wide-ranging, collaborative network is invaluable. We are grateful for the experience. #biotech

Collaboration is key in developing and delivering the best therapeutic options possible to our patients. Meetings like Ophthalmology Innovation Source and CTS Retina bring #retina providers and industry thought leaders together to make it all possible. Thank you, Bindu Manne and Arshad M. Khanani for the mention and for sharing our excitement and passion for #FightingBlindness.